Novo Nordisk Crashes 17% After Warning 2026 Sales Could Decline Up to 13% as the GLP-1 Price War Reshapes Big Pharma
Novo Nordisk shares plunged 17% after the Ozempic and Wegovy maker warned that 2026 sales could fall 5% to 13%, the first revenue decline in years driven by US pricing pressure and intensifying competition from Eli Lilly.